New paradigms in sepsis: From prevention to protection of failing microcirculation

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 10, 2015, Pages 1743-1756

  Hawiger, J ^a   Veach, R A ^a   Zienkiewicz, J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genome; Infection; Inflammation; Microcirculation; Septic shock

Indexed keywords

CELL PROTEIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; KARYOPHERIN; MENINGOCOCCUS VACCINE; MYELOID DIFFERENTIATION FACTOR 88; STEROL REGULATORY ELEMENT BINDING PROTEIN; STREPTOCOCCUS VACCINE; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; VIRULENCE FACTOR; AUTACOID;

ACUTE KIDNEY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; BACTERIAL INFECTION; CAUSE OF DEATH; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; EBOLA HEMORRHAGIC FEVER; EDEMA; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HUMAN; HUMAN GENOME; HYPOTENSION; IN SITU HYBRIDIZATION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MENINGOCOCCEMIA; MENINGOCOCCOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL GENOME; MICROCIRCULATION; MICROORGANISM DETECTION; MULTIPLE ORGAN FAILURE; MYCOSIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; SEPSIS; SEPTICEMIA; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; THROMBOCYTOPENIA; VACCINATION; VASOPLEGIA; VIRUS INFECTION; ANIMAL; BACTERIAL GENOME; FUNGAL GENOME; GENETIC PREDISPOSITION; GENETICS; HOST PATHOGEN INTERACTION; METABOLISM; MICROBIOLOGY; MICROVASCULATURE; MORTALITY; PATHOPHYSIOLOGY; PHENOTYPE; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VIROLOGY; VIRUS GENOME;

ANIMALS; GENETIC PREDISPOSITION TO DISEASE; GENOME, BACTERIAL; GENOME, FUNGAL; GENOME, VIRAL; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLAMMATION MEDIATORS; MICROCIRCULATION; MICROVESSELS; PHENOTYPE; RISK FACTORS; SEPSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84942983959     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13061     Document Type: Article

References (100)

1. Metchnikoff E. Lectures On The Comparative Pathology of Inflammation, Delivered at the Pasteur Instutute in 1891. London: Kegan Paul, 1893.
2. Hawiger J. Physiology of hemostasis: cellular aspects. In: Nathan DG, Oski FA, eds. Hematology of Infancy and Childhood, 4th edn. Philadelphia, London, Toronto, Montreal, Sidney, Tokyo: W.B. Saunders Company, 1992: 1495-512.
3. Skibsted S, Jones AE, Puskarich MA, Arnold R, Sherwin R, Trzeciak S, Schuetz P, Aird WC, Shapiro NI. Biomarkers of endothelial cell activation in early sepsis. Shock. 2013; 39: 427-32.
4. Ye X, Ding J, Zhou X, Chen G, Liu SF. Divergent roles of endothelial NF-kappaB in multiple organ injury and bacterial clearance in mouse models of sepsis. J Exp Med 2008; 205: 1303-15.
5. London NR, Zhu W, Bozza FA, Smith MC, Greif DM, Sorensen LK, Chen L, Kaminoh Y, Chan AC, Passi SF, Day CW, Barnard DL, Zimmerman GA, Krasnow MA, Li DY. Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Sci Transl Med. 2010; 2:23ra19.
6. Trzeciak S, Cinel I, Phillip Dellinger R, Shapiro NI, Arnold RC, Parrillo JE, Hollenberg SM. Resuscitating the microcirculation in sepsis: the central role of nitric oxide, emerging concepts for novel therapies, and challenges for clinical trials. Academic Emergency Medicine: Official Journal of the Society for Academic Emergency Medicine. 2008;15:399-413.
7. National Heart Lung and Blood Institute Working Group Report. Blood Systems Response to Sepsis [Internet]. 2010. www.nhlbi.nih.gov/meetings/workshops/bsrts.htm.
8. Hawiger J, Musser JM. How to approach genome wars in sepsis? Crit Care 2011; 15: 1007.
9. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
10. Vincent JL. Dear SIRS, I'm sorry to say that I don't like you. Crit Care Med 1997; 25: 372-4.
11. Rhee C, Gohil S, Klompas M. Regulatory mandates for sepsis care-reasons for caution. The New England Journal of Medicine. 2014; 370: 1673-6.
12. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS International sepsis definitions conference. Intensive Care Med 2003; 29: 530-8.
13. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
14. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 2000; 6: 886-9.
15. Xu W, Edwards MR, Borek DM, Feagins AR, Mittal A, Alinger JB, Berry KN, Yen B, Hamilton J, Brett TJ, Pappu RV, Leung DW, Basler CF, Amarasinghe GK. Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe 2014; 16: 187-200.
16. Wong G, Kobinger GP. Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak. Clin Microbiol Rev 2015; 28: 593-601.
17. Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 2004; 4: 487-98.
18. Pauli NT, Kim HK, Falugi F, Huang M, Dulac J, Henry Dunand C, Zheng NY, Kaur K, Andrews SF, Huang Y, DeDent A, Frank KM, Charnot-Katsikas A, Schneewind O, Wilson PC. Staphylococcus aureus infection induces protein A-mediated immune evasion in humans. J Exp Med. 2014;211:2331-9.
19. Flick MJ, Du X, Prasad JM, Raghu H, Palumbo JS, Smeds E, Hook M, Degen JL. Genetic elimination of the binding motif on fibrinogen for the S. aureus virulence factor ClfA improves host survival in septicemia. Blood. 2013;121:1783-94.
20. Sun H, Ringdahl U, Homeister JW, Fay WP, Engleberg NC, Yang AY, Rozek LS, Wang X, Sjobring U, Ginsburg D. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 2004; 305: 1283-6.
21. DiGiandomenico A, Veach RA, Zienkiewicz J, Moore DJ, Wylezinski LS, Hutchens MA, Hawiger J. The, "genomic storm" induced by bacterial endotoxin is calmed by a nuclear transport modifier that attenuates localized and systemic inflammation. PLoS ONE 2014; 9: e110183.
22. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K. International study of the prevalence and outcomes of infection in intensive care units. JAMA: The Journal of the American Medical Association. 2009; 302: 2323-9.
23. Beutler BA. TLRs and innate immunity. Blood 2009; 113: 1399-407.
24. Adamzik M, Hamburger T, Petrat F, Peters J, de Groot H, Hartmann M. Free hemoglobin concentration in severe sepsis: methods of measurement and prediction of outcome. Crit Care 2012; 16: R125.
25. Angus DC, Yang L, Kong L, Kellum JA, Delude RL, Tracey KJ, Weissfeld L. Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med 2007; 35: 1061-7.
26. Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, Taylor FB, Esmon NL, Lupu F, Esmon CT. Extracellular histones are major mediators of death in sepsis. Nat Med 2009; 15: 1318-21.
27. McDonald B, Urrutia R, Yipp BG, Jenne CN, Kubes P. Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. Cell Host Microbe 2012; 12: 324-33.
28. Woywodt A, Blann AD, Kirsch T, Erdbruegger U, Banzet N, Haubitz M, Dignat-George F. Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a definition and a consensus protocol. J Thromb Haemost 2006; 4: 671-7.
29. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96.
30. Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia FF, Shofer FS, Goyal M. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010; 38: 1045-53.
31. Sharawy N. Vasoplegia in septic shock: do we really fight the right enemy? J Crit Care 2014; 29: 83-7.
32. Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med 2014; 20: 195-203.
33. Goldenberg NM, Steinberg BE, Slutsky AS, Lee WL. Broken barriers: a new take on sepsis pathogenesis. Sci Transl Med. 2011; 3: 88 ps25.
34. Rauch S, Gough P, Kim HK, Schneewind O, Missiakas D. Vaccine protection of leukopenic mice against Staphylococcus aureus bloodstream infection. Infect Immun 2014; 82: 4889-98.
35. Qiao H, Liu Y, Veach RA, Wylezinski L, Hawiger J. The adaptor CRADD/RAIDD controls activation of endothelial cells by proinflammatory stimuli. J Biol Chem 2014; 289: 21973-83.
36. Sanchez A, Wagoner KE, Rollin PE. Sequence-based human leukocyte antigen-B typing of patients infected with Ebola virus in Uganda in 2000: identification of alleles associated with fatal and nonfatal disease outcomes. J Infect Dis 2007; 196(Suppl. 2): S329-36.
37. Picard C, Casanova JL, Puel A. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IkappaBalpha deficiency. Clin Microbiol Rev 2011; 24: 490-7.
38. Conley ME, Casanova JL. Discovery of single-gene inborn errors of immunity by next generation sequencing. Curr Opin Immunol 2014; 30: 17-23.
39. Collins FS, Varmus H. A new initiative on precision medicine. The New England Journal of Medicine. 2015; 372: 793-5.
40. Kanapathipillai R, Henao Restrepo AM, Fast P, Wood D, Dye C, Kieny MP, Moorthy V. Ebola vaccine-an urgent international priority. The New England Journal of Medicine. 2014; 371: 2249-51.
41. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. The New England Journal of Medicine. 2013; 369: 155-63.
42. Help Protect Your Preteen and Teen Against Meningococcal Disease. National Center for Immunizations and Respiratory Diseases; 2014. www.cdc.gov/features/meningococcal. Accessed 21 April 2014.
43. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7: 353-64.
44. Hawiger J. Innate immunity and inflammation: a transcriptional paradigm. Immunol Res 2001; 23: 99-109.
45. Liu Y, Major AS, Zienkiewicz J, Gabriel CL, Veach RA, Moore DJ, Collins RD, Hawiger J. Nuclear transport modulation reduces hypercholesterolemia, atherosclerosis, and fatty liver. J Am Heart Assoc 2013; 2: e000093.
46. Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, Gao H, Hayden DL, Hennessy L, Moore EE, Minei JP, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Brownstein BH, Mason PH, Baker HV, Finnerty CC, et al. A genomic storm in critically injured humans. J Exp Med 2011; 208: 2581-90.
47. Janz DR, Bastarache JA, Rice TW, Bernard GR, Warren MA, Wickersham N, Sills G, Oates JA, Roberts LJ 2nd, Ware LB. Randomized, placebo-controlled trial of acetaminophen for the reduction of oxidative injury in severe sepsis: the acetaminophen for the reduction of oxidative injury in severe sepsis trial. Crit Care Med 2015; 43: 534-41.
48. Esmon CT, Esmon NL. The link between vascular features and thrombosis. Annu Rev Physiol 2011; 73: 503-14.
49. Angus DC, van der Poll T. Severe sepsis and septic shock. The New England Journal of Medicine. 2013; 369: 2063.
50. Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence 2014; 5: 66-72.
51. Tabet F, Vickers KC, Cuesta Torres LF, Wiese CB, Shoucri BM, Lambert G, Catherinet C, Prado-Lourenco L, Levin MG, Thacker S, Sethupathy P, Barter PJ, Remaley AT, Rye KA.HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nat Commun. 2014; 5: 3292.
52. Sun X, Icli B, Wara AK, Belkin N, He S, Kobzik L, Hunninghake GM, Vera MP, Registry M, Blackwell TS, Baron RM, Feinberg MW. MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation. J Clin Investig 2012; 122: 1973-90.
53. Deck MK, Anderson ES, Buckner RJ, Colasante G, Coull JM, Crystal B, Della Latta P, Fuchs M, Fuller D, Harris W, Hazen K, Klimas LL, Lindao D, Meltzer MC, Morgan M, Shepard J, Stevens S, Wu F, Fiandaca MJ. Multicenter evaluation of the Staphylococcus QuickFISH method for simultaneous identification of Staphylococcus aureus and coagulase-negative staphylococci directly from blood culture bottles in less than 30 minutes. J Clin Microbiol 2012; 50: 1994-8.
54. Veach RA, Zienkiewicz J, Collins RD, Hawiger J. Lethality in a murine model of pulmonary anthrax is reduced by combining nuclear transport modifier with antimicrobial therapy. PLoS ONE 2012; 7: e30527.
55. Levin J, Poore TE, Young NS, Margolis S, Zauber NP, Townes AS, Bell WR. Gram-negative sepsis: detection of endotoxemia with the limulus test. With studies of associated changes in blood coagulation, serum lipids, and complement. Ann Intern Med 1972; 76: 1-7.
56. Sun H, Xu Y, Sitkiewicz I, Ma Y, Wang X, Yestrepsky BD, Huang Y, Lapadatescu MC, Larsen MJ, Larsen SD, Musser JM, Ginsburg D. Inhibitor of streptokinase gene expression improves survival after group A streptococcus infection in mice. Proc Natl Acad Sci USA 2012; 109: 3469-74.
57. Andreasen AS, Krabbe KS, Krogh-Madsen R, Taudorf S, Pedersen BK, Moller K. Human endotoxemia as a model of systemic inflammation. Curr Med Chem 2008; 15: 1697-705.
58. Zienkiewicz J, Armitage A, Hawiger J. Targeting nuclear import shuttles, importins/karyopherins alpha by a peptide mimicking the NFkappaB1/p50 nuclear localization sequence. J Am Heart Assoc 2013; 2: e000386.
59. Liu D, Zienkiewicz J, DiGiandomenico A, Hawiger J. Suppression of acute lung inflammation by intracellular peptide delivery of a nuclear import inhibitor. Mol Ther 2009; 17: 796-802.
60. Liu D, Li C, Chen Y, Burnett C, Liu XY, Downs S, Collins RD, Hawiger J. Nuclear import of proinflammatory transcription factors is required for massive liver apoptosis induced by bacterial lipopolysaccharide. J Biol Chem 2004; 279: 48434-42.
61. Rauch PJ, Chudnovskiy A, Robbins CS, Weber GF, Etzrodt M, Hilgendorf I, Tiglao E, Figueiredo J-L, Iwamoto Y, Theurl I, Gorbatov R, Waring MT, Chicoine AT, Mouded M, Pittet MJ, Nahrendorf M, Weissleder R, Swirski FK. Innate response activator B cells protect against microbial sepsis. Science (New York, Ny) 2012; 335: 597-601.
62. Weber GF, Chousterman BG, He S, Fenn AM, Nairz M, Anzai A, Brenner T, Uhle F, Iwamoto Y, Robbins CS, Noiret L, Maier SL, Zonnchen T, Rahbari NN, Scholch S, Klotzsche-von Ameln A, Chavakis T, Weitz J, Hofer S, Weigand MA, et al. Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis. Science 2015; 347: 1260-5.
63. Langley RJ, Tsalik EL, van Velkinburgh JC, Glickman SW, Rice BJ, Wang C, Chen B, Carin L, Suarez A, Mohney RP, Freeman DH, Wang M, You J, Wulff J, Thompson JW, Moseley MA, Reisinger S, Edmonds BT, Grinnell B, Nelson DR, et al. An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med. 2013; 5: 195ra95.
64. Tomaiuolo M, Stalker TJ, Welsh JD, Diamond SL, Sinno T, Brass LF. A systems approach to hemostasis: 2. Computational analysis of molecular transport in the thrombus microenvironment. Blood. 2014; 124: 1816-23.
65. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008; 8: 776-87.
66. Venkata C, Kashyap R, Farmer JC, Afessa B. Thrombocytopenia in adult patients with sepsis: incidence, risk factors, and its association with clinical outcome. Journal of Intensive Care. 2013; 1: 9.
67. Voves C, Wuillemin WA, Zeerleder S. International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients. Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis. 2006; 17: 445-51.
68. Ivanciu L, Krishnaswamy S, Camire RM. New insights into the spatiotemporal localization of prothrombinase in vivo. Blood 2014; 124: 1705-14.
69. Camerer E, Cornelissen I, Kataoka H, Duong DN, Zheng YW, Coughlin SR. Roles of protease-activated receptors in a mouse model of endotoxemia. Blood 2006; 107: 3912-21.
70. Spiel AO, Firbas C, Mayr FB, Leitner JM, Schmidt B, Knobl P, Varadi K, Jilma B. The effects of supra-normal protein C levels on markers of coagulation, fibrinolysis and inflammation in a human model of endotoxemia. Thromb Haemost 2005; 94: 1148-55.
71. Zarychanski R, Abou-Setta AM, Kanji S, Turgeon AF, Kumar A, Houston DS, Rimmer E, Houston BL, McIntyre L, Fox-Robichaud AE, Hebert P, Cook DJ, Fergusson DA. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis. Crit Care Med 2015; 43: 511-8.
72. Yu OM, Heller Brown J. GPCR and RhoA-stimulated transcriptional responses mediating inflammation, differentiation and cell proliferation. Mol Pharmacol 2015; 88: 171-80.
73. Kaneider NC, Leger AJ, Agarwal A, Nguyen N, Perides G, Derian C, Covic L, Kuliopulos A. 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol 2007; 8: 1303-12.
74. Aman J, van Bezu J, Damanafshan A, Huveneers S, Eringa EC, Vogel SM, Groeneveld ABJ, Vonk Noordegraaf A, van Hinsbergh VWM, van Nieuw Amerongen GP. Effective treatment of edema and endothelial barrier dysfunction with imatinib. Circulation 2012; 126: 2728-38.
75. Letsiou E, Rizzo AN, Sammani S, Naureckas P, Jacobson JR, Garcia JG, Dudek SM. Differential and opposing effects of imatinib on LPS- and ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol 2015; 308: L259-69.
76. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013; 13: 260-8.
77. Shalova IN, Lim JY, Chittezhath M, Zinkernagel AS, Beasley F, Hernandez-Jimenez E, Toledano V, Cubillos-Zapata C, Rapisarda A, Chen J, Duan K, Yang H, Poidinger M, Melillo G, Nizet V, Arnalich F, Lopez-Collazo E, Biswas SK. Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1alpha. Immunity 2015; 42: 484-98.
78. Turer EE, Tavares RM, Mortier E, Hitotsumatsu O, Advincula R, Lee B, Shifrin N, Malynn BA, Ma A. Homeostatic MyD88-dependent signals cause lethal inflamMation in the absence of A20. J Exp Med 2008; 205: 451-64.
79. Carow B, Rottenberg ME. SOCS3, a Major Regulator of Infection and Inflammation. Front Immunol 2014; 5: 58.
80. Jo D, Liu D, Yao S, Collins RD, Hawiger J. Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat Med 2005; 11: 892-8.
81. Fletcher TC, DiGiandomenico A, Hawiger J. Extended anti-inflammatory action of a degradation-resistant mutant of cell-penetrating suppressor of cytokine signaling 3. The Journal of Biological Chemistry. 2010; 285: 18727-36.
82. Ridder DA, Lang MF, Salinin S, Roderer JP, Struss M, Maser-Gluth C, Schwaninger M. TAK1 in brain endothelial cells mediates fever and lethargy. J Exp Med 2011; 208: 2615-23.
83. Hughes CG, Morandi A, Girard TD, Riedel B, Thompson JL, Shintani AK, Pun BT, Ely EW, Pandharipande PP. Association between endothelial dysfunction and acute brain dysfunction during critical illness. Anesthesiology. 2013;118:631-9.
84. Morandi A, Rogers BP, Gunther ML, Merkle K, Pandharipande P, Girard TD, Jackson JC, Thompson J, Shintani AK, Geevarghese S, Miller RR 3rd, Canonico A, Cannistraci CJ, Gore JC, Ely EW, Hopkins RO. The relationship between delirium duration, white matter integrity, and cognitive impairment in intensive care unit survivors as determined by diffusion tensor imaging: the VISIONS prospective cohort magnetic resonance imaging study*. Crit Care Med 2012; 40: 2182-9.
85. Iwashyna TJ, Ely EW, Smith DM, Langa KM.Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA: The Journal of the American Medical Association. 2010;304:1787-94.
86. Hou JW. Natural course of neonatal progeroid syndrome. Pediatrics and Neonatology. 2009; 50: 102-9.
87. Ragnauth CD, Warren DT, Liu Y, McNair R, Tajsic T, Figg N, Shroff R, Skepper J, Shanahan CM. Prelamin A acts to accelerate smooth muscle cell senescence and is a novel biomarker of human vascular aging. Circulation 2010; 121: 2200-10.
88. Sethman CR, Hawiger J. The innate immunity adaptor SARM translocates to the nucleus to stabilize lamins and prevent DNA fragmentation in response to pro-apoptotic signaling. PLoS One 2013; 8: e70994.
89. Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 2014; 40: 315-27.
90. Jung TW, Hwang HJ, Hong HC, Choi HY, Yoo HJ, Baik SH, Choi KM. Resolvin D1 reduces ER stress-induced apoptosis and triglyceride accumulation through JNK pathway in HepG2 cells. Mol Cell Endocrinol 2014; 391: 30-40.
91. Wynn JL, Scumpia PO, Delano MJ, O'Malley KA, Ungaro R, Abouhamze A, Moldawer KL. Increased mortality and altered immunity in neonatal sepsis produced by generalized peritonitis. Shock. 2007; 28: 675-83.
92. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, Lopez CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013; 110: 3507-12.
93. Osuchowski MF, Remick DG, Lederer JA, Lang CH, Aasen AO, Aibiki M, Azevedo LC, Bahrami S, Boros M, Cooney R, Cuzzocrea S, Jiang Y, Junger WG, Hirasawa H, Hotchkiss RS, Li XA, Radermacher P, Redl H, Salomao R, Soebandrio A, et al. Abandon the mouse research ship? Not just yet!. Shock. 2014; 41: 463-75.
94. Takao K, Miyakawa T. Genomic responses in mouse models greatly mimic human inflammatory diseases. Proc Natl Acad Sci USA. 2015 (published ahead of print August 4, 2014); 112: 1167-72.
95. Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Buller HR, van Deventer SJ, Hack CE, ten Cate JW, Rosenberg RD. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Investig 1994; 93: 114-20.
96. Marshall JC, Deitch E, Moldawer LL, Opal S, Redl H, van der Poll T. Preclinical models of shock and sepsis: what can they tell us? Shock. 2005; 24(Suppl 1): 1-6.
97. Torio CM, Andrews RM. National inpatient hospital costs: the most expensive conditions by payer, 2011: statistical brief #160. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet], Rockville, MD: Agency for Health Care Policy and Research (US), 2013 Aug. www.ncbi.nlm.nih.gov/books/NBK169005/. Accessed August 2013.
98. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-10.
99. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, Hale EC, Newman NS, Schibler K, Carlo WA, Kennedy KA, Poindexter BB, Finer NN, Ehrenkranz RA, Duara S, Sanchez PJ, O'Shea TM, Goldberg RN, van Meurs KP, Faix RG, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010; 126: 443-56.
100. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med 2013; 41: 1167-74.